Read by QxMD icon Read

Neuro-oncology Practice

Sarah M Scott, Jason M Ashford, Kellie N Clark, Karen Martin-Elbahesh, Heather M Conklin
Background: Few researchers routinely disseminate results to participants; however, there is increasing acknowledgment that benefits of returning results outweigh potential risks. Our objective was to determine whether use of specific guidelines developed by the Children's Oncology Group (COG) when preparing a lay summary would aid in understanding results. Specifically, to determine if caregivers of childhood cancer survivors found a lay summary comprehensive, easy to understand, and helpful following participation in a computerized cognitive training program...
August 2018: Neuro-oncology Practice
Kyle R Noll, Mariana E Bradshaw, Jeffrey S Weinberg, Jeffrey S Wefel
Background: Cancer and treatment-related neurocognitive dysfunction has the potential to significantly disrupt the lives of survivors. While neurocognitive functioning is known to predict aspects of patient-reported quality of life in individuals with glioma, little is known regarding the association between neurocognitive functioning and clinician-rated functional independence. Methods: Newly diagnosed patients with glioma in the left (n = 73; 49% glioblastoma) or right (n = 30; 57% glioblastoma) temporal lobe completed comprehensive neuropsychological testing...
August 2018: Neuro-oncology Practice
Solomon N Ambe, Kristopher A Lyon, Damir Nizamutdinov, Ekokobe Fonkem
Background: Although rare, primary central nervous system (CNS) tumors are associated with significant morbidity and mortality. Texas is a representative sample of the United States population given its large population, ethnic disparities, geographic variations, and socio-economic differences. This study used Texas data to determine if variations in incidence trends and rates exist among different ethnicities in Texas. Methods: Data from the Texas Cancer Registry from 1995 to 2013 were examined...
August 2018: Neuro-oncology Practice
Michelle J Naughton, L Douglas Case, Ann Peiffer, Michael Chan, Volker Stieber, Dennis Moore, Steven Falchuk, James Piephoff, William Edenfield, Jeffrey Giguere, Monica Loghin, Edward G Shaw, Stephen R Rapp
Background: The health-related quality of life (HRQL) and fatigue of brain cancer survivors treated with donepezil or placebo for cognitive symptoms after radiation therapy were examined. Methods: One hundred ninety-eight patients who completed >30 Gy fractionated whole or partial brain irradiation at least 6 months prior to enrollment were randomized to either placebo or donepezil (5 mg for 6 weeks followed by 10 mg for 18 weeks) in a phase 3 trial. A neurocognitive battery, the Functional Assessment of Cancer Therapy-Brain (FACT-Br) and the Functional Assessment of Chronic Illness Therapy (FACIT)-fatigue, was administered at baseline, 12 weeks, and 24 weeks...
May 2018: Neuro-oncology Practice
Ori Barzilai, Mary-Kate Amato, Lily McLaughlin, Anne S Reiner, Shahiba Q Ogilvie, Eric Lis, Yoshiya Yamada, Mark H Bilsky, Ilya Laufer
Background: Patient-reported outcomes (PRO) represent an important measure of cancer therapy effect. For patients with metastatic epidural spinal cord compression (MESCC), hybrid therapy using separation surgery and stereotactic radiosurgery preserves neurologic function and provides tumor control. There is currently a paucity of data reporting PRO after such combined modality therapy for MESCC. Delineation of hybrid surgery-radiosurgery therapy effect on PRO validates the hybrid approach as an effective therapy resulting in meaningful symptom relief...
May 2018: Neuro-oncology Practice
Yahya Ghazwani, Ibrahim Qaddoumi, Johnnie K Bass, Shengjie Wu, Jason Chiang, Frederick Boop, Amar Gajjar, Zsila Sadighi
Background: Hearing loss may occur in patients with posterior fossa low-grade glioma who undergo surgery. Methods: We retrospectively reviewed 217 patients with posterior fossa low-grade glioma, including 115 for whom results of hearing tests performed after surgery and before chemotherapy or radiation therapy were available. We explored the association of UHL with age at diagnosis, sex, race, tumor location, extent of resection, posterior fossa syndrome, ventriculoperitoneal shunt placement, and histology...
May 2018: Neuro-oncology Practice
Karen Gauvain, Maria Rosana Ponisio, Amy Barone, Michael Grimaldi, Ephraim Parent, Hayden Leeds, Manu Goyal, Joshua Rubin, Jonathan McConathy
Background: Noninvasively predicting early response to therapy in recurrent pediatric brain tumors provides a challenge. 3,4-dihydroxy-6-[18 F]fluoro-L-phenylalanine (18 F-FDOPA) PET/MRI has not been previously studied as a tool to evaluate early response to antiangiogenic therapy in children. The purpose of this study was to evaluate the safety and feasibility of using 18 F-FDOPA PET/MRI to assess response to bevacizumab in children with relapsed brain tumors. Materials and Methods: Six patients with recurrent gliomas (5 low-grade, 1 high-grade) planned to undergo treatment with bevacizumab were enrolled...
March 2018: Neuro-oncology Practice
Karen Manias, Simrandip K Gill, Niloufar Zarinabad, Paul Davies, Martin English, Daniel Ford, Lesley MacPherson, Ina Nicklaus-Wollenteit, Adam Oates, Guirish Solanki, Jenny Adamski, Martin Wilson, Andrew C Peet
Background: Magnetic resonance spectroscopy (MRS) aids noninvasive diagnosis of pediatric brain tumors, but use in clinical practice is not well documented. We aimed to review clinical use of MRS, establish added value in noninvasive diagnosis, and investigate potential impact on patient care. Methods: Sixty-nine children with lesions imaged using MRS and reviewed by the tumor board from 2014 to 2016 met inclusion criteria. Contemporaneous MRI diagnosis, spectroscopy analysis, histopathology, and clinical information were reviewed...
March 2018: Neuro-oncology Practice
Quinn T Ostrom, Karen Devine, Jordonna Fulop, Yingli Wolinsky, Peter Liao, Lindsay Stetson, Marta Couce, Andrew E Sloan, Jill S Barnholtz-Sloan
The growth of precision medicine has made access to biobanks with high-quality, well-annotated neuro-oncology biospecimens critical. Developing and maintaining neuro-oncology biobanks is best accomplished through multidisciplinary collaboration between clinicians and researchers. Balancing the needs and leveraging the skills of all stakeholders in this multidisciplinary effort is of utmost importance. Collaboration with a multidisciplinary team of clinicians, health care team members, and institutions, as well as patients and their families, is essential for access to participants in order to obtain informed consent, collect samples under strict standard operating procedures, and accurate and relevant clinical annotation...
December 2017: Neuro-oncology Practice
Cassie N Kline, Roger J Packer, Eugene I Hwang, David R Raleigh, Steve Braunstein, Corey Raffel, Pratiti Bandopadhayay, David A Solomon, Mariam Aboian, Soonmee Cha, Sabine Mueller
Medulloblastoma is the most common malignant brain tumor affecting children. These tumors are high grade with propensity to metastasize within the central nervous system and, less frequently, outside the neuraxis. Recent advancements in molecular subgrouping of medulloblastoma refine diagnosis and improve counseling in regards to overall prognosis. Both are predicated on the molecular drivers of each subgroup-WNT-activated, SHH-activated, group 3, and group 4. The traditional therapeutic mainstay for medulloblastoma includes a multimodal approach with surgery, radiation, and multiagent chemotherapy...
September 2017: Neuro-oncology Practice
Jacqueline B Stone, Joanne F Kelvin, Lisa M DeAngelis
Background: Fertility preservation (FP) is an infrequently addressed issue for young adults with primary brain tumors. Given the improved prognosis and enhanced technology in reproductive medicine, more primary brain tumor patients see procreation as feasible, making the discussion of FP increasingly important. The goals of this study were to describe patients who received FP counseling by a fertility nurse specialist (FNS) and determine which sociodemographic and disease-related factors predict acceptance of referral to a reproductive specialist...
March 2017: Neuro-oncology Practice
Katrina A Morris, John F Golding, Patrick R Axon, Shazia Afridi, Claire Blesing, Rosalie E Ferner, Dorothy Halliday, Raj Jena, Pieter M Pretorius, D Gareth Evans, Martin G McCabe, Allyson Parry
Background: NF2 patients develop multiple nervous system tumors including bilateral vestibular schwannomas (VS). The tumors and their surgical treatment are associated with deafness, neurological disability, and mortality.Medical treatment with bevacizumab has been reported to reduce VS growth and to improve hearing. In addition to evaluating these effects, this study also aimed to determine other important consequences of treatment including patient-reported quality of life and the impact of treatment on surgical VS rates...
December 2016: Neuro-oncology Practice
Motomasa Furuse, Naosuke Nonoguchi, Toshihiko Kuroiwa, Susumu Miyamoto, Yoshiki Arakawa, Jun Shinoda, Kazuhiro Miwa, Toshihiko Iuchi, Koji Tsuboi, Kiyohiro Houkin, Shunsuke Terasaka, Yusuke Tabei, Hideo Nakamura, Motoo Nagane, Kazuhiko Sugiyama, Mizuhiko Terasaki, Tatsuya Abe, Yoshitaka Narita, Nobuhito Saito, Akitake Mukasa, Kuniaki Ogasawara, Takaaki Beppu, Toshihiro Kumabe, Tadashi Nariai, Naohiro Tsuyuguchi, Eiji Nakatani, Shoko Kurisu, Yoko Nakagawa, Shin-Ichi Miyatake
BACKGROUND: Brain radiation necrosis (BRN) can be a complication of radiotherapy for primary and secondary brain tumors, as well as head and neck tumors. Since vascular endothelial growth factor (VEGF) is also a vascular permeability factor in the brain, bevacizumab, a humanized antibody that inhibits VEGF, would be expected to reduce perilesional edema that often accompanies BRN. METHODS: Patients with surgically untreatable, symptomatic BRN refractory to conventional medical treatments (eg, corticosteroid, anticoagulants, or hyperbaric oxygen therapy) were enrolled...
December 2016: Neuro-oncology Practice
Jennifer C Thigpen, Matthew Pearson, Kristen E Robinson, Charissa Andreotti, Jennifer P Dunbar, Kelly H Watson, Leandra Dejardins, Lindsay Holmes, Rebecca Byram, Claire Fraley, Bruce E Compas
BACKGROUND: Establishing a presurgical baseline of neurocognitive functioning for pediatric brain tumor patients is a high priority to identify level of functioning prior to medical interventions. However, few studies have obtained adequate samples of presurgery assessments. METHODS: This study examines the feasibility of completing tests to assess pre-surgical neurocognitive functioning in 59 identified pediatric brain tumor patients. RESULTS: Eighty-five percent of patients ( n = 50) were referred by the neurosurgery team before surgery and 83% of patients ( n = 49) enrolled in the study...
December 2016: Neuro-oncology Practice
Yan Ji, Rachel Isaksson Vogel, Emil Lou
BACKGROUND: Pituitary carcinomas (PC) and atypical pituitary adenomas (APA) are rare variants of pituitary tumors for which no evidence-based treatment currently exists. We sought to determine whether temozolomide represents an effective chemotherapeutic option for patients with PC and APA. METHODS: A systematic review was performed using all published cases of PC and APA treated with temozolomide, and for which information on treatment regimen, clinical response, and survival could be identified...
September 2016: Neuro-oncology Practice
(no author information available yet)
No abstract text is available yet for this article.
June 2016: Neuro-oncology Practice
Sergio Cabrera, Kim Edelstein, Warren P Mason, Maria Carmela Tartaglia
BACKGROUND: Personality changes following brain tumors may be due to disruption of frontal-subcortical networks. The relation between personality changes and tumor parameters such as volumes of the surgical cavity, residual tumor, or nonspecific white matter abnormalities is unknown. In this study we examined the relation between these tumor parameters and abnormal behaviors typically associated with frontal lobe dysfunction. METHODS: Thirty-one patients with intracranial tumors who completed the Frontal Systems Behavior Scale (FrSBe) during clinical neuropsychological assessment and had a solitary, well-delimited brain lesion on MRI within 3 months of that assessment were included...
June 2016: Neuro-oncology Practice
Anne Long, Georgia K B Halkett, Elizabeth A Lobb, Thérèse Shaw, Elizabeth Hovey, Anna K Nowak
BACKGROUND: Few studies have explored the unmet needs of carers of people with high-grade glioma. We aimed to determine carers' levels of distress during treatment, understand their support needs and explore predictors of distress. METHODS: Carers of people with high-grade glioma undergoing chemoradiotherapy were recruited to this prospective, longitudinal cohort study. Carers completed the validated Supportive Care Needs Survey, Brain Tumour Specific Supportive Care Needs Scale, Distress Thermometer (DT), and General Health Questionnaire (GHQ-12)...
June 2016: Neuro-oncology Practice
Alison White, Vicki Fabian, Kerrie McDonald, Anna K Nowak
BACKGROUND: Diagnostic pathology reports inform management plans for patients with glioma, and there is an increasing clinical need for molecular testing. We assessed the quality of histopathology reports of grade III/IV gliomas. METHODS: Reports were obtained as part of a tumor biobank. From 720 pathology reports, 594 eligible reports were assessed for 28 elements derived from published checklists. A summary quality score incorporated 9 critical parameters for clinical decision making: diagnosis using World Health Organization 2007 criteria; cell type; grade; narrative supporting cell type and grade; absence of equivocal language; conclusion reporting cell type and grade; and conclusion aligned with report narrative...
June 2016: Neuro-oncology Practice
Terri Rice, Daniel H Lachance, Annette M Molinaro, Jeanette E Eckel-Passow, Kyle M Walsh, Jill Barnholtz-Sloan, Quinn T Ostrom, Stephen S Francis, Joseph Wiemels, Robert B Jenkins, John K Wiencke, Margaret R Wrensch
During the past six years, researchers have made major progress identifying common inherited genetic variation that increases risk for primary adult glioma. This paper summarizes knowledge about rare familial cancer syndromes that include adult glioma and reviews the available literature on the more recently discovered common inherited variation. Ten independent inherited variants in eight chromosomal regions have been convincingly associated with increased risk for adult glioma. Most of these variants increase relative risk of primary adult glioma by 20% to 40%, but the TP53 variant rs78378222 confers a two-fold relative risk (ie, 200%), and rs557505857 on chromosome 8 confers a six-fold relative risk of IDH-mutated astrocytomas and oligodendroglial tumors (ie, 600%)...
March 2016: Neuro-oncology Practice
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"